Much of Inflammatix's scientific work is developed in the San Francisco Bay, California. Now, the company also has a laboratory in Lisbon, at LACS Conde d’Óbidos.


Inflammatix's work essentially consists of developing a “medical diagnosis based on the logic of measuring the response of the immune system”, as the CTO, João Fonseca, tells us. In addition, the company embraces the concept of personalized medicine, that takes into account the specificities of the organism of each human being as it manages to “measure each person's immune response to find a more adjusted treatment”, adds João Fonseca.


One of the main goals is to prevent the number of cases of septicemia, a widespread infection that can be fatal and is quite common in hospitals. “Before COVID-19, one in five people who died in hospitals ended up dying with septicemia”, explains João Fonseca, who also explains what one of Inflmmatix's most important innovations consists of: InSep. “It is a test that allows an early diagnosis of the risk of generalized infection. The test gives a level of risk of viral infection, risk of bacterial infection and risk of severity of infection several days before any other current test”. In short, it can be said that "this test will help to save lives with the early diagnosis of patients at higher risk".


Moving on to treatment, Inflammatix's CTO talks about another of the highlighted solutions designed by the company: the Virabac test. This “allows us to understand more accurately if a person has a viral or bacterial infection. It's like a better version of other tests like CRP [another in vitro diagnostic test], helping the doctor to decide whether or not to give antibiotics” to the patient.

Regarding the panorama of research and development of health solutions, João Fonseca has no doubt that the world may change in the coming years, largely due to the vaccines recently developed to fight the COVID-19 pandemic. According to the CTO of Inflammatix - who also wants to work in the oncology field - "these COVID-19 vaccine solutions are excellent news in the fight against cancer, because they were all the result of research and development programs for personalized vaccines in oncology".

Recently, the company closed an investment round of more than 100 million euros, with "American venture capital, of Silicon Valley", an amount that went "far beyond expectations" (Inflammatix as  expecting to get around 40 million in this round), but, according to the CTO, “the project and the team are so interesting” that the value ended up surpassing the most optimistic forecasts.

Answering to the question “If the history of Inflammatix were a movie, what would it be?”, João Fonseca replied that the company “doesn't have a movie yet, but it's coming soon and it will certainly be an important Hollywood production”. However, the CTO of Inflammatix knows which film shows Biosurfit's path: The Pursuit of Happiness. This other company, also linked to cutting-edge technology in the health area, a partner of LACS regarding the testing of COVID-19 and of which João Fonseca is Chairman, has had a path very similar to the main character of this film, in terms of to “doubts, achievements and a way to make a dream come true”.

15 Jul

LACS welcomes a new member: Inflammatix!

Other News


The creative cluster has custom-made offices, a space to study and a plan for working outside the home.

Know more

Coworks offer free days to help remote workers

Know more
We Stand Together Site V1 (2)

LACS announces its decision to fully subsidize vaccination in its flexible and coworking spaces

Know more

Future of work: Ideas from Miguel Rodrigues

Know more